AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth Care
AnticoagulantsThrombosisVenous ThrombosisLupus Coagulation InhibitorCoronary ThrombosisBlood CoagulationSinus Thrombosis, IntracranialWarfarinProtein CHeparinProthrombin TimeIntracranial ThrombosisPartial Thromboplastin TimeCarotid Artery ThrombosisThromboembolismAntithrombinsAcenocoumarolHeparin, Low-Molecular-WeightBlood Coagulation TestsFactor XaRodenticidesThrombophiliaHemorrhagePhenindioneProthrombinAntiphospholipid SyndromeThrombin TimeBlood Coagulation FactorsProtein S4-HydroxycoumarinsInternational Normalized RatioThrombomodulinFactor VAntibodies, AntiphospholipidIntracranial Embolism and ThrombosisThrombinVenous ThromboembolismHemostasisFibrinolytic AgentsPhlebographybeta-AlaninePlatelet Aggregation InhibitorsAntibodies, AnticardiolipinAntithrombin IIISagittal Sinus ThrombosisThromboplastinVitamin KBlood Coagulation DisordersActivated Protein C ResistanceProtein S DeficiencyIliac VeinFemoral VeinPhenprocoumonProtein C DeficiencyAdministration, OralThrombophlebitisbeta 2-Glycoprotein IUpper Extremity Deep Vein ThrombosisFibrin Fibrinogen Degradation ProductsAspirinTreatment OutcomeEnoxaparinBleeding TimeHirudinsRisk FactorsAntithrombin III DeficiencyPortal VeinPipecolic AcidsCerebral VeinsPulmonary EmbolismCoagulantsBlood PlateletsTime FactorsHeparin AntagonistsPlatelet AggregationVena Cava, InferiorFactor XFibrinolysisFibrinRecurrenceCavernous Sinus ThrombosisThiophenesFollow-Up StudiesPlatelet ActivationFactor VaAtrial FibrillationThrombectomyRetrospective StudiesFibrinogenDicumarolStentsThrombolytic TherapyProspective StudiesVena Cava FiltersLateral Sinus ThrombosisPopliteal VeinRodent ControlCardiolipinsJugular VeinsDisseminated Intravascular Coagulation
HeparinAtrial fibrillationDOACsThinnersHemostasisAnticoagulationPatientsCancer-associated thrombosisOralAcuteHaemostasisVenous ThromboembolismArterialCerebralClotsThrombolyticMedicationsWarfarinPortal Vein ThromTake an anticoagulantClass of anticoagulantPlateletTherapyClotLupus anticoagulantInferior venaThrombinPulmonary embolismsStrokeAntithrombin2022TherapeuticClinically suspectedPreventionSymptomsThromboticDiagnosisTreatmentsSkin ulcers2023FibrinolysisProteinTreatmentThrombophlebitisDeep venous
Heparin11
  • Common anticoagulants include warfarin and heparin. (wikipedia.org)
  • Heparin therapy and oral anticoagulant therapy must always follow a course of thrombolysis. (medscape.com)
  • Commonly, you'll be given an injection of the anticoagulant heparin right away to prevent clots from forming. (healthline.com)
  • Prevention of deep vein thrombosis by Panax notoginseng saponins combined with low-molecular-weight heparin. (greenmedinfo.com)
  • Use of a non-heparin anticoagulant may be indicated if patient is 4 to 42 days post-vaccine with all other facets of the syndrome pending PF4 ELISA testing and additional CBCs. (hematology.org)
  • Heparin has long been used as a blood thinner, or anticoagulant, for patients with blood clotting disorders or after surgery to prevent complications. (medicalxpress.com)
  • Heparin (from Ancient Greek ηπαρ ( hepar ), liver), also known as unfractionated heparin , a highly sulfated glycosaminoglycan, is widely used as an injectable anticoagulant, and has the highest negative charge density of any known biological molecule. (medicalxpress.com)
  • Heparin is a heterogeneous group of straight-chain anionic mucopolysaccharides, called glycosaminoglycans, having anticoagulant properties. (nih.gov)
  • Heparin Sodium Injection, USP is a sterile solution of heparin sodium derived from porcine intestinal mucosa, standardized for anticoagulant activity, in water for injection. (nih.gov)
  • Small amounts of heparin in combination with antithrombin III (heparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. (nih.gov)
  • Usually, the anticoagulant drug called heparin is used to treat blood clots. (cdc.gov)
Atrial fibrillation6
DOACs12
Thinners3
  • Anticoagulants, commonly known as blood thinners, are chemical substances that prevent or reduce coagulation of blood, prolonging the clotting time. (wikipedia.org)
  • Treatment for DVT usually involves taking blood thinners (anticoagulants) for at least 3 months. (healthwise.net)
  • The main side effect of anticoagulants or blood thinners is bleeding. (medindia.net)
Hemostasis3
Anticoagulation7
  • The goal of this document is to provide guidance from the Anticoagulation Forum, a North American organization of anticoagulation providers, regarding use of anticoagulant therapies in patients with COVID-19. (springer.com)
  • Reports of elevated risk of thrombosis associated with coronavirus disease-19 (COVID-19) have led frontline providers to consider the empiric use of therapeutic anticoagulation for hospitalized patients even in the absence of documented or clinically suspected thrombosis. (springer.com)
  • The use of anticoagulants is a decision based upon the risks and benefits of anticoagulation. (wikipedia.org)
  • Factor V Leiden) - can lead to deep vein thrombosis Mechanical heart valves Myocardial infarction Pulmonary embolism Restenosis from stents Cardiopulmonary bypass (or any other surgeries requiring temporary aortic occlusion) Heart failure In these cases, anticoagulation therapy can prevent formation of dangerous clots or prevent growth of clots. (wikipedia.org)
  • Standardized communication during transitions of care regarding anticoagulation may reduce anticoagulant ADEs. (the-hospitalist.org)
  • Anticoagulation, either administered via the parenteral (heparins and fondaparinux), or the oral route [vitamin K antagonists (VKAs)], represents the mainstay for prevention and treatment of venous thromboembolism (VTE), including deep-vein thrombosis (DVT), pulmonary embolism (PE), and superficial-vein thrombosis (SVT), since more than half a century. (frontiersin.org)
  • Methods and Results We conducted a retrospective cohort study including all participants from ACTION-CVT (Anticoagulation in the Treatment of Cerebral Venous Thrombosis) study who had dates of neurologic symptom onset and CVT diagnosis available. (bvsalud.org)
Patients23
  • Clinicians around the globe are challenged with rapidly identifying reasonable diagnostic, monitoring and anticoagulant strategies to safely and effectively manage these patients. (springer.com)
  • We discuss in-hospital and post-discharge venous thromboembolism (VTE) prevention, treatment of suspected but unconfirmed VTE, laboratory monitoring of COVID-19, associated anticoagulant therapies, and essential elements for optimized transitions of care specific to patients with COVID-19. (springer.com)
  • The document also addresses key strategies to minimize COVID-19 exposure risk for patients taking chronic anticoagulant medications. (springer.com)
  • Expert physicians diagnosed deep vein thrombosis in 200 patients, corresponding to an overall prevalence of 18 percent. (medindia.net)
  • However, a case report and literature review by Naesens et al of community-acquired MRSA infections of the central nervous system, including cavernous sinus thrombosis, showed that patients treated with linezolid had a better outcome than those treated with vancomycin. (medscape.com)
  • Percutaneous transcatheter treatment of patients with deep venous thrombosis (DVT) consists of thrombus removal with catheter-directed thrombolysis, mechanical thrombectomy, angioplasty, and/or stenting of venous obstructions. (medscape.com)
  • Cancer is a risk factor for DVT, particularly in older patients and in patients with recurrent thrombosis. (merckmanuals.com)
  • Campello E, Spiezia L, Simion C, Rosin E, Bulato C, Radu C, Gavasso S, Simioni P. Plasma Levels of Procoagulant and Anticoagulant Factors in Patients with Acute Cancer-associated Thrombosis [abstract]. (isth.org)
  • For the clinical management of NCCM patients, an appropriate stratification of the thromboembolic risk is of utmost importance for a timely initiation of anticoagulant therapy. (nih.gov)
  • We concluded that OC users, and patients with factor V Leiden, the prothrombin G20 120A mutation, and hyperhomocysteinemia are at a significantly increased risk of cerebral vein thrombosis. (greenmedinfo.com)
  • The aim of the MAC project is to collect real-life clinical information in unselected patients given oral anticoagulants for venous thromboembolism, during a 5-year follow-up period. (frontiersin.org)
  • Thus, we embarked in a cohort study, designed to evaluate in the "real-word" setting the outcome of unselected Italian patients with VTE treated with anticoagulants, which will be followed-up for up to 5 years. (frontiersin.org)
  • Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis. (mayo.edu)
  • Kidney function decline in patients taking oral anticoagulant drugs is an important topic that has been overlooked in previous clinical trials," says lead author Xiaoxi Yao, Ph.D. "Even our past work at Mayo Clinic has been primarily focused on risks for stroke or bleeding. (medindia.net)
  • However, the researchers took it a step further and separated out the patients taking non-vitamin K antagonist oral anticoagulants from those taking warfarin. (medindia.net)
  • Note that patients who have undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy with retroperitoneal lymph node dissection can incidentally demonstrate ovarian vein thrombosis on contrast-enhanced computed tomography [CT] scanning. (medscape.com)
  • The anticoagulant properties of FV were discovered during investigations of individual patients and follow the great tradition of bed-to-bench and bench-to-bed research in the coagulation field. (lu.se)
  • Le syndrome des antiphospholipides a été diagnostiqué chez 11 patients : neuf patients ont été traités avec succès par photocoagulation au laser associant un traitement anticoagulant et antiagrégant. (who.int)
  • Informed include lupus anticoagulant and anticardio- consent was obtained from patients and lipin antibodies [ 2,3 ]. (who.int)
  • In particular, retinal vascular occlusions says for anticardiolipin antibodies and lupus in patients with primary APS, i.e. with an- anticoagulant. (who.int)
  • Co-Occurrence of Interleukin-6 Receptor Asp358Ala Variant and High Plasma Levels of IL-6: An Evidence of IL-6 Trans-Signaling Activation in Deep Vein Thrombosis (DVT) Patients. (cdc.gov)
  • Direct oral anticoagulants for deep vein thrombosis among patients with hereditary thrombophilia-A cohort study. (cdc.gov)
  • two patients were also diagnosed with splanchnic* and portal vein thrombosis. (cdc.gov)
Cancer-associated thrombosis1
  • The role of coagulation factors to the development of cancer-associated thrombosis (CAT) has not been completely clarified. (isth.org)
Oral15
  • Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. (wikipedia.org)
  • Newer non-vitamin K antagonist oral anticoagulants appear to have fewer life-threatening bleeding events compared to warfarin. (wikipedia.org)
  • In vitro studies and anecdotal clinical reports have suggested that clinically significant rebound hypercoagulability may occur after discontinuation of oral anticoagulants (OACs), such as vitamin K antagonists and ximelagatran, for venous thromboembolism (VTE). (medscape.com)
  • Oral anticoagulants. (bmj.com)
  • The use of direct oral anticoagulants vs. vitamin K antagonists is also discussed with important implications for patient treatment and prognosis. (nih.gov)
  • Funding The study was part of the research project entitled " New oral anticoagulants: relationship between drug concentration and anticoagulant effect " (IP-2016-06-8208), which was funded by the Croatian Scientific Foundation. (thieme-connect.com)
  • It is concluded that the contribution of K 2 vitamins (menaquinones) to the human vitamin K status is presently underestimated, and that their potential interference with oral anticoagulant treatment needs to be investigated. (karger.com)
  • Vermeer C, Hamulyák K: Pathophysiology of vitamin K deficiency and oral anticoagulants. (karger.com)
  • Because of the delayed registration of direct oral anticoagulants in Italy, scarce real-life data on such treatments is available for the Italian population. (frontiersin.org)
  • Take a direct oral anticoagulant (DOAC) to prevent stroke. (healthlinkbc.ca)
  • Their study, published online today in the Journal of the American College of Cardiology, is the most recent in a series of studies seeking to determine the safety and efficacy of non-vitamin K antagonist oral anticoagulants versus the long-standard warfarin. (medindia.net)
  • However, our findings indicate that the non-vitamin K antagonist oral anticoagulants as a group are associated with less injury to kidneys than warfarin. (medindia.net)
  • We found that non-vitamin K antagonist oral anticoagulants, as a group, were associated with reduced risk of adverse kidney outcomes," says Dr. Noseworthy. (medindia.net)
  • Since non-vitamin K antagonist oral anticoagulants have a different drug mechanism than warfarin, researchers have hypothesized that non-vitamin K antagonist oral anticoagulants may be related to better renal outcomes. (medindia.net)
  • we recommend a systematic search for antiphospholipid antibodies in occlusions of unexplained origin and laser photocoagulation treatment and long-term oral anticoagulant and anti-aggregant therapy. (who.int)
Acute20
Haemostasis2
Venous Thromboembolism1
Arterial7
  • Thrombosis occurs when a blood clot blocks arteries from carrying oxygenated blood from the heart (arterial thrombosis) or veins from carrying oxygen-depleted blood back to the heart (venous thrombosis). (inova.org)
  • Arterial thrombosis may result from arteriosclerosis, which involves hardening of the arteries where fatty or calcium deposits cause the arterial walls to thicken. (inova.org)
  • When arterial thrombosis occurs in the coronary arteries (arteries that branch from the aorta to provide blood to the heart muscle), it can lead to heart attacks. (inova.org)
  • When arterial thrombosis occurs in the brain circulation, it can lead to strokes or lack of oxygen to other organs. (inova.org)
  • Our Vascular Services team treats vein and arterial problems, including blood clotting and thrombosis. (inova.org)
  • Junto con la proteína C inhibe la acción de los factores VIIIa y Va. Una deficiencia en proteína S (DEFICIENCIA EN PROTEÍNA S) puede llevar a trombosis venosa y arterial recurrente. (bvsalud.org)
  • can lead to recurrent venous and arterial thrombosis. (bvsalud.org)
Cerebral5
  • Cerebral venous thrombosis (CVT) is a relatively rare condition that results from thrombosis of the superficial or deep venous sinuses of the brain. (aku.edu)
  • There is no evidence to indicate that adding anticoagulant therapy to standard treatment has a benefit for people with cerebral small vessel disease but not dementia and there is an increased risk of a person with this disease experiencing a bleed with this approach. (wikipedia.org)
  • Background Identifying factors associated with delayed diagnosis of cerebral venous thrombosis (CVT) can inform future strategies for early detection. (bvsalud.org)
  • BACKGROUND: Seizures are common in cerebral venous thrombosis (CVT). (bvsalud.org)
  • In these cases, a type of blood clot called cerebral venous sinus thrombosis (CVST) was seen in combination with low levels of blood platelets (thrombocytopenia). (cdc.gov)
Clots5
  • Deep vein thrombosis (DVT) is a condition where blood clots develop usually in the deep veins of the legs. (medindia.net)
  • You might then continue treatment by taking a different anticoagulant, such as warfarin, to help ensure new clots don't form. (healthline.com)
  • Anticoagulants can stop a DVT from getting larger and can prevent new clots from forming. (harvard.edu)
  • In a condition called deep vein thrombosis , clots form in the deep veins of the body, usually in the legs. (radiologyinfo.org)
  • Warfarin is an anticoagulant, which means that it thins the blood, preventing blood clots from forming. (medlineplus.gov)
Thrombolytic3
  • Anticoagulants are closely related to antiplatelet drugs and thrombolytic drugs by manipulating the various pathways of blood coagulation. (wikipedia.org)
  • Direct intrathrombus injection of the thrombolytic agent protects the medication from deactivation by circulating inhibitors and achieves higher drug concentration at the site of thrombosis with a lower total dose than would be used for systemic intravenous thrombolytic therapy. (medscape.com)
  • Thrombolytic therapy offers significant advantages over conventional anticoagulant therapy, including the prompt resolution of symptoms, the prevention of pulmonary embolism, the restoration of normal venous circulation, the preservation of venous valvular function, and the prevention of postthrombotic syndrome. (medscape.com)
Medications2
  • As such, providers should employ a methodical and thoughtful approach to the use of high-risk anticoagulant medications for both prophylactic and therapeutic purposes. (springer.com)
  • As a class of medications, anticoagulants are used in therapy for thrombotic disorders. (wikipedia.org)
Warfarin1
Portal Vein Throm4
Take an anticoagulant2
  • To help prevent DVT, you might take an anticoagulant medicine. (healthwise.net)
  • You may first want to decide whether to take an anticoagulant at all. (healthlinkbc.ca)
Class of anticoagulant1
  • Risk of bleeding is dependent on the class of anticoagulant agent used, patient's age, and pre-existing health conditions. (wikipedia.org)
Platelet2
Therapy5
  • The goals of endovascular therapy include reducing the severity and duration of lower-extremity symptoms, preventing PE, diminishing the risk of recurrent venous thrombosis, and preventing postthrombotic syndrome (PTS). (medscape.com)
  • When an invasive procedure is considered, the benefit must be weighed against the added risk compared with standard anticoagulant therapy. (medscape.com)
  • These real-world findings may guide selection of initial anticoagulant therapy, according to authors of the paper. (the-hospitalist.org)
  • Kumar S, Haigh JR, Rhodes LE, Peaker S, Davies JA, Roberts BE, Feely MP: Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. (karger.com)
  • The combination of anticoagulant and intravenous (IV) antibiotic therapy is the treatment of choice. (medscape.com)
Clot10
Lupus anticoagulant1
  • In general, healthy subjects do not have a prolonged aPTT and do not have lupus anticoagulant (LA) activity. (medscape.com)
Inferior vena2
  • Researchers have discovered that few adverse events may be associated with the use of inferior vena cava filters to help prevent deep vein thrombosis from developing into pulmonary embolisms, according to a new study jointly published by Johnson et al in the Journal of Vascular and Interventional. (ascopost.com)
  • In cases of clinically significant thrombosis, inferior vena cava (IVC) filter placement should be considered. (medscape.com)
Thrombin1
Pulmonary embolisms1
  • We've compiled a list of symptoms, causes, and treatment for deep vein thrombosis and pulmonary embolisms with information from MedlinePlus and the National Heart, Lung, and Blood Institute. (medlineplus.gov)
Stroke2
Antithrombin1
  • During several decades, the knowledge base of the natural anticoagulants has greatly increased and we have also learned about antiinflammatory and cytoprotective activities expressed by antithrombin and activated protein C (APC). (lu.se)
20221
  • Arteriosclerosis, thrombosis, and vascular biology 2022 Jul 101161ATVBAHA122317746. (cdc.gov)
Therapeutic1
  • Duxbury B: Therapeutic control of anticoagulant treatment. (karger.com)
Clinically suspected1
  • In a study of more than 1,000 outpatients with clinically suspected deep vein thrombosis, diagnosis was performed by physician experts in vascular ultrasonography and GPs trained in the technique. (medindia.net)
Prevention1
  • On April 13, 2021, the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) suggested pausing administration of the AD26.COV2.S Johnson & Johnson (JJ) vaccine to allow investigation of several cases of severe thrombosis with thrombocytopenia occurring post-vaccination. (hematology.org)
Symptoms4
Thrombotic1
Diagnosis3
  • More rapid diagnosis, directly obtained by GPs in primary care, could improve appropriate management of deep vein thrombosis and help address the growing need for professionals trained in compression ultrasonography. (medindia.net)
  • Ultrasound (US), magnetic resonance imaging (MRI), and CT scanning with contrast are the best radiologic modalities for making the diagnosis of ovarian vein thrombosis. (medscape.com)
  • Angiography can help make the diagnosis of ovarian vein thrombosis, but this technique is not usually performed because of the availability of noninvasive, cross-sectional imaging methods. (medscape.com)
Treatments1
  • Compare and contrast all of the anticoagulant treatments available with this simple dynamic table. (thrombosisadviser.com)
Skin ulcers1
  • Venous thrombosis can obstruct the veins or damage their one-way valves, allowing blood to pool, which causes chronic pain, swelling, skin discoloration and skin ulcers. (inova.org)
20231
  • Thrombosis research 2023 6 228 151-162. (cdc.gov)
Fibrinolysis2
Protein3
  • A poor anticoagulant response to activated protein C (APC) in an activated partial thromboplastin time (aPTT) assay (APC resistance) was recently reported to be a cause of familial thrombophilia. (nih.gov)
  • The discovery of APC resistance, caused by FVLeiden, as a thrombosis risk factor resulted in the identification of FV as an APC cofactor working in synergy with protein S in the regulation of FVIIIa in the Xase complex. (lu.se)
  • The FXa-inhibitory activity of TFPIα is synergistically stimulated by FV-Short and protein S. The circulating FV-Short/protein S/TFPIα complex concentration is normally low (≈0.2 nM) but provides an anticoagulant threshold. (lu.se)
Treatment6
  • Treatment is with anticoagulants. (merckmanuals.com)
  • RCTs of varying durations of OAC treatment of VTE that include VTE recurrence (or extension) data for more than 2 months after discontinuation of anticoagulants. (medscape.com)
  • Treatment reduces the risk of pulmonary embolism and other complications and typically involves anticoagulant medication and compression stockings. (healthline.com)
  • Pycnogenol may alleviate adverse effects in oncologic treatment, e.g. deep vein thrombosis. (greenmedinfo.com)
  • They are the mainstay of treatment for pulmonary embolism and deep vein thrombosis. (radiologyinfo.org)
  • Over the past 60 years, due to the advancement of hemo- the Work Group and tasked it with planning, developing, dialysis (HD) technology and the introduction of medical reviewing, and disseminating appropriate HD treatment insurance, dialysis treatment has become widespread, en- guidelines in accordance with international standards. (bvsalud.org)
Thrombophlebitis2
Deep venous3